Last reviewed · How we verify
standard chemotherapy for colorectal cancer
standard chemotherapy for colorectal cancer is a Chemotherapy Small molecule drug developed by University Hospital, Rouen. It is currently in Phase 3 development for Metastatic colorectal cancer.
Standard chemotherapy for colorectal cancer works by interfering with the growth of cancer cells, ultimately leading to cell death.
Standard chemotherapy for colorectal cancer works by interfering with the growth of cancer cells, ultimately leading to cell death. Used for Metastatic colorectal cancer.
At a glance
| Generic name | standard chemotherapy for colorectal cancer |
|---|---|
| Sponsor | University Hospital, Rouen |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the disruption of DNA replication and cell division, which are essential processes for cancer cell proliferation. The exact mechanism can vary depending on the specific chemotherapy agent used, but the overall goal is to slow or stop the growth of cancer cells.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Nausea
- Fatigue
- Hair loss
- Diarrhea
- Vomiting
Key clinical trials
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (PHASE1, PHASE2)
- Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis (NA)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (PHASE2)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) (PHASE3)
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (PHASE2, PHASE3)
- TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard chemotherapy for colorectal cancer CI brief — competitive landscape report
- standard chemotherapy for colorectal cancer updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI
Frequently asked questions about standard chemotherapy for colorectal cancer
What is standard chemotherapy for colorectal cancer?
How does standard chemotherapy for colorectal cancer work?
What is standard chemotherapy for colorectal cancer used for?
Who makes standard chemotherapy for colorectal cancer?
What drug class is standard chemotherapy for colorectal cancer in?
What development phase is standard chemotherapy for colorectal cancer in?
What are the side effects of standard chemotherapy for colorectal cancer?
Related
- Drug class: All Chemotherapy drugs
- Manufacturer: University Hospital, Rouen — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Compare: standard chemotherapy for colorectal cancer vs similar drugs
- Pricing: standard chemotherapy for colorectal cancer cost, discount & access